Controlled Release Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlled Release Technologies

Catalent is the global leader in advanced drug technologies, providing tablets, capsules and other formulations for sustained/modified drug substance release, launching more than 50 products into all the major markets.

Catalent matches each project with a competent, enthusiastic team, to ensure all work is performed according to customers’ timelines and budget. Whether a controlled-release technology is needed to manage a product’s lifecycle in the marketplace, or for a specific clinical, pharmacodynamics, or pharmacokinetic profile, Catalent can help to achieve the desired outcome.

In 2014 Catalent will celebrate 80 years of softgel manufacturing and has continually delivered innovation with specialised global manufacturing and innovative technological enhancements such as chewable softgels and enteric coatings, to enable delayed-release of the active ingredient with targeted absorption.

Further technology advancements in controlled release include Catalent’s OSDrC® OptiDoseTM technology, which enables design of dividable, multi-layer, single or multi-core tablets with a variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing process.  This expands tableting capabilities in many areas that differentiate beyond existing technologies.

OptiDose technology enables single or multiple APIs in a single tablet, with different release profiles. With shown improvement in mass variability between layers, OptiDose offers tablet design to minimise cross-layer interaction and improved product stability.

 

Catalent Pharma Solutions
Website: www.catalent.com

E-mail: info@catalent.com 
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here